cancer diagnostics

ANGLE plc announced all resolutions were passed at its 2025 Annual General Meeting. The global leader in liquid biopsy technology, known for its Parsortix® PC1 System, focuses on circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. The company offers clinical services and diagnostic products, backed by over 100 peer-reviewed publications.